Pentagestrone acetate

Pentagestrone acetate (PGA), sold under the brand names Gestovis and Gestovister, is a progestin which was described in the literature in 1960 and was introduced by Vister in Italy in 1961.[1][2][3] It is the 3-cyclopentyl enol ether of 17α-hydroxyprogesterone acetate.[4] PGA, along with quingestrone (the 3-cyclopentyl enol ether of progesterone), is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone.[5]

Pentagestrone acetate
Clinical data
Trade namesGestovis, Gestovister
Other namesPGA; Gestovis; 17α-Acetoxyprogesterone 3-cyclopentyl enol ether
Routes of
administration		By mouth
Drug classProgestogen; Progestin; Progestogen ether; Progestogen ester
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC28H40O4
Molar mass440.615 g/mol g·mol−1
3D model (JSmol)

PGA is orally active, was provided in 10 and 20 mg capsules, and has been used to treat habitual abortion and menstrual disorders at a dosage of 10 to 20 mg/day.[6] It has been said to have equivalent potency to intramuscular progesterone.[6] The combination of 20 mg/day PGA and 100 μg/day mestranol is an effective ovulation inhibitor in women.[7][8] The effective dosage of PGA in the menstrual delay test has been studied.[9]

Chemistry
See also: List of progestogens, Progestogen ester, and List of progestogen esters

PGA, also known as 17α-acetoxyprogesterone 3-cyclopentyl enol ether, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone.[1]

See also

References
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 943–. ISBN 978-1-4757-2085-3.
  2. Drugs Available Abroad. Gale Research. 1991. ISBN 978-0-8103-7177-4.
  3. P. H. List; L. Hörhammer (12 March 2013). Chemikalien und Drogen Teil A: N-Q. Springer-Verlag. pp. 508–. ISBN 978-3-642-65035-2.
  4. Camille Georges Wermuth (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 731–. ISBN 978-0-08-056877-5.
  5. Revue générale des sciences pures et appliquées et bulletin de l'Association française pour l'avancement des sciences. Société d'édition d'enseignement supérieur. 1964. [[...] Ercoli (1960) developed cyclopentyl enol ethers of progesterone (Luteovis) and acetoxy progesterone (Gestovis), which have almost exactly the same properties as dydrogesterone.]
  6. "Gestovis". South African Medical Journal. 40 (5): 99. January 1966. ISSN 0256-9574. Comopharm (Pty) Limited. on behalf of Vister Laboratories, announce the introduction of Gestovis, and supply the following information: Gestovis is a new highly effective oral progesterone derivative (cyclopentylenol-ether of 17-alpha-acetoxyprogesterone) for the treatment of threatened and habitual abortion and menstrual disturbances. Gestovis is efficacious orally at the same dose as parenterally administered progesterone. Dosage. 10 - 20 mg. daily or as necessary. Presentation. Available in capsules of 10 and 20 mg.
  7. Gregory Pincus (3 September 2013). The Control of Fertility. Elsevier. pp. 221–. ISBN 978-1-4832-7088-3.
  8. Current Medicine and Drugs. 1962. p. 32. Gestovis (3-cyclo-pentyl-enol ether of 17a acetoxyprogesterone) is a potent non-oestrogenic preparation but does not give very good cycle control. In doses of 20 mg daily from the fifth to twenty-fifth day of the cycle it will inhibit ovulation.
  9. Edgren RA, Sturtevant FM (August 1976). "Potencies of oral contraceptives". Am. J. Obstet. Gynecol. 125 (8): 1029–38. doi:10.1016/0002-9378(76)90804-8. PMID 952300.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.